PubMed Journals Articles About "Late John Mendlein Joins Reinventing Biotech Lineup April" RSS

20:47 EST 1st February 2015 | BioPortfolio

Late John Mendlein Joins Reinventing Biotech Lineup April PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Late John Mendlein Joins Reinventing Biotech Lineup April articles that have been published worldwide.

More Information about "Late John Mendlein Joins Reinventing Biotech Lineup April" on BioPortfolio

We have published hundreds of Late John Mendlein Joins Reinventing Biotech Lineup April news stories on BioPortfolio along with dozens of Late John Mendlein Joins Reinventing Biotech Lineup April Clinical Trials and PubMed Articles about Late John Mendlein Joins Reinventing Biotech Lineup April for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Late John Mendlein Joins Reinventing Biotech Lineup April Companies in our database. You can also find out about relevant Late John Mendlein Joins Reinventing Biotech Lineup April Drugs and Medications on this site too.

Showing "Late John Mendlein Joins Reinventing Biotech Lineup April" PubMed Articles 1–25 of 3,700+

Extremely Relevant

Biotech drugs too little, too late for Ebola outbreak.

Suspect Filler Similarity in Eyewitness Lineups: A Literature Review and a Novel Methodology.

Eyewitness lineups typically contain a suspect (guilty or innocent) and fillers (known innocents). The degree to which fillers should resemble the suspect is a complex issue that has yet to be resolved. Previously, researchers have voiced concern that eyewitnesses would be unable to identify their target from a lineup containing highly similar fillers; however, our literature review suggests highly similar fillers have only rarely been shown to have this effect. To further examine the effect of highly simil...


Double-Blind Photo Lineups Using Actual Eyewitnesses: An Experimental Test of a Sequential Versus Simultaneous Lineup Procedure.

Eyewitnesses (494) to actual crimes in 4 police jurisdictions were randomly assigned to view simultaneous or sequential photo lineups using laptop computers and double-blind administration. The sequential procedure used in the field experiment mimicked how it is conducted in actual practice (e.g., using a continuation rule, witness does not know how many photos are to be viewed, witnesses resolve any multiple identifications), which is not how most lab experiments have tested the sequential lineup. No signi...

Reinventing tech transfer.

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL.

Current HIV-1 vaccines based on the HIV-1 envelope glycoprotein spike (Env), the only relevant target for broadly neutralizing antibodies, are unable to induce protective immunity. Env immunogenicity can be enhanced by fusion to costimulatory molecules involved in B cell activation, such as APRIL and CD40L. Here, we found that Env-APRIL signaled through the two receptors, BCMA and TACI. In rabbits, Env-APRIL induced significantly higher antibody responses against Env compared to unconjugated Env, while the ...

Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.

Cytokines play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Among the cytokines that regulate B cell homeostasis is a proliferation-inducing ligand (APRIL). This study aimed to determine whether serum levels of APRIL are raised in patients with SLE and correlate with disease activity or proinflammatory cytokines production, or both. Serum APRIL, interleukin-17 (IL-17), IL-4 and interferon gamma (IFN-γ) levels were measured in forty patients with SLE and 30 healthy controls. ...

Reinventing the Health Services Researcher.

Reinventing neutron science in Europe.

John St John Long: quackery and manslaughter.

Pfizer joins PD-L1 pursuit.

Biotech on the bounce in 3Q14.

University biotech patenting 2013.

Third-quarter biotech job picture.

Public biotech 2013-the numbers.

Benchmarking biotech and pharmaceutical product development.

Erratum: University biotech patenting 2013.

Big-cap buying bonanza trickles down to small biotech.

Taiwan biotech buoyed by colossal financings.

Erratum: Public biotech 2013-the numbers.

Improving biotech education through gamified laboratory simulations.

Small biotech steers HDAC inhibitor to clinic.

Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients.

We have previously shown that the tumor necrosis factor family member a proliferation-inducing ligand (APRIL) enhances intestinal tumor growth in various preclinical tumor models. Here, we have investigated whether APRIL serum levels at time of surgery predict survival in a large cohort of colorectal cancer (CRC) patients. We measured circulating APRIL levels in a cohort of CRC patients (n=432) using a novel validated monoclonal APRIL antibody (hAPRIL.133) in an enzyme-linked immunosorbent assay (ELISA) set...

Erratum: Biotech's wellspring: the health of private biotech in 2013.

The cost of kidney transplant over time.

Background-Kidney transplant improves quality of life and survival compared with dialysis. Despite advances in immunosuppressant regimens and the prevention and treatment of acute rejection, graft survival rates have not improved significantly in the past decade. Although the clinical effectiveness of these regimens has been studied, the impact of changes over time on cost has not.Methods-Costs of kidney transplant were compared between 2 periods demarcated by a programmatic change from cyclosporine (early)...

Prevalence and risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre in Switzerland.

We sought to identify reasons for late human immunodeficiency virus (HIV) testing or late presentation for care.

Search BioPortfolio:

PubMed Database Quicklinks